Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mereo BioPharma Group plc - American Depositary Shares (NQ:MREO)

2.190 +0.060 (+2.82%)
Streaming Delayed Price Updated: 10:13 AM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Mereo BioPharma Group plc - American Depositary Shares

< Previous 1 2 Next >
Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Provides Update on Lead Clinical Programs
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
From Mereo BioPharma Group plc
Via GlobeNewswire
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Mereo BioPharma to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
From Mereo BioPharma Group plc
Via GlobeNewswire
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)
From Ultragenyx Pharmaceutical Inc.; Mereo Biopharma
Via GlobeNewswire
Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update
From Mereo BioPharma Group plc
Via GlobeNewswire
Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
Mereo BioPharma to Present at the Jefferies Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma’s Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma to Participate in Fireside Chat at the 22nd Annual Needham Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease
From Mereo BioPharma Group plc
Via GlobeNewswire
Mereo BioPharma to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.